Trinity Biotech's Enhanced Prostate Cancer Test Achieves 85% Clinical Accuracy, Marking Entry into Oncology Market
TRIB sits 42% above its 52-week low of $0.48.
Summary
Trinity Biotech announced successful clinical results for an enhanced version of its EpiCapture™ prostate cancer test, demonstrating 85% clinical accuracy (AUC) in a study of 750 patient samples. This test, which integrates machine learning and patient ethnicity for higher precision risk prediction, marks the company's strategic first entry into the precision oncology diagnostics market. For a micro-cap company, this represents a significant new growth avenue in the multi-billion dollar prostate cancer care market, diversifying its product portfolio beyond its existing diabetes monitoring solutions. The company plans to commercialize EpiCapture™ as a proprietary Laboratory Developed Test (LDT) through its New York State certified laboratory. Investors will now watch for details on the commercial rollout and initial market adoption.
At the time of this announcement, TRIB was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $0.48 to $3.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.